Literature DB >> 19052217

Aggregated, wild-type prion protein causes neurological dysfunction and synaptic abnormalities.

Roberto Chiesa1, Pedro Piccardo, Emiliano Biasini, Bernardino Ghetti, David A Harris.   

Abstract

The neurotoxic forms of the prion protein (PrP) that cause neurodegeneration in prion diseases remain to be conclusively identified. Considerable evidence points to the importance of noninfectious oligomers of PrP in the pathogenic process. In this study, we describe lines of Tg(WT) transgenic mice that over-express wild-type PrP by either approximately 5-fold or approximately 10-fold (depending on whether the transgene array is, respectively, hemizygous or homozygous). Homozygous but not hemizygous Tg(WT) mice develop a spontaneous neurodegenerative illness characterized clinically by tremor and paresis. Both kinds of mice accumulate large numbers of punctate PrP deposits in the molecular layer of the cerebellum as well as in several other brain regions, and they display abnormally enlarged synaptic terminals accompanied by a dramatic proliferation of membranous structures. The over-expressed PrP in Tg(WT) mice assembles into an insoluble form that is mildly protease-resistant and is recognizable by aggregation-specific antibodies, but that is not infectious in transmission experiments. Together, our results demonstrate that noninfectious aggregates of wild-type PrP are neurotoxic, particularly to synapses, and they suggest common pathogenic mechanisms shared by prion diseases and nontransmissible neurodegenerative disorders associated with protein misfolding.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19052217      PMCID: PMC2646838          DOI: 10.1523/JNEUROSCI.3109-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  54 in total

1.  Non-infectious aggregates of the prion protein react with several PrPSc-directed antibodies.

Authors:  Emiliano Biasini; M Esa Seegulam; Brianna N Patti; Laura Solforosi; Andrea Z Medrano; Heather M Christensen; Assunta Senatore; Roberto Chiesa; R Anthony Williamson; David A Harris
Journal:  J Neurochem       Date:  2008-06-01       Impact factor: 5.372

2.  Identification of two prion protein regions that modify scrapie incubation time.

Authors:  S Supattapone; T Muramoto; G Legname; I Mehlhorn; F E Cohen; S J DeArmond; S B Prusiner; M R Scott
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Primary myopathy and accumulation of PrPSc-like molecules in peripheral tissues of transgenic mice expressing a prion protein insertional mutation.

Authors:  R Chiesa; A Pestronk; R E Schmidt; W G Tourtellotte; B Ghetti; P Piccardo; D A Harris
Journal:  Neurobiol Dis       Date:  2001-04       Impact factor: 5.996

4.  Transmissible and genetic prion diseases share a common pathway of neurodegeneration.

Authors:  R S Hegde; P Tremblay; D Groth; S J DeArmond; S B Prusiner; V R Lingappa
Journal:  Nature       Date:  1999-12-16       Impact factor: 49.962

5.  Accumulation of protease-resistant prion protein (PrP) and apoptosis of cerebellar granule cells in transgenic mice expressing a PrP insertional mutation.

Authors:  R Chiesa; B Drisaldi; E Quaglio; A Migheli; P Piccardo; B Ghetti; D A Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

6.  Synapse loss associated with abnormal PrP precedes neuronal degeneration in the scrapie-infected murine hippocampus.

Authors:  M Jeffrey; W G Halliday; J Bell; A R Johnston; N K MacLeod; C Ingham; A R Sayers; D A Brown; J R Fraser
Journal:  Neuropathol Appl Neurobiol       Date:  2000-02       Impact factor: 8.090

7.  Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers.

Authors:  Matthew Townsend; James P Cleary; Tapan Mehta; Jacki Hofmeister; Sylvain Lesne; Eugene O'Hare; Dominic M Walsh; Dennis J Selkoe
Journal:  Ann Neurol       Date:  2006-12       Impact factor: 10.422

8.  Prion protein deposition and abnormal synaptic protein expression in the cerebellum in Creutzfeldt-Jakob disease.

Authors:  I Ferrer; B Puig; R Blanco; E Martí
Journal:  Neuroscience       Date:  2000       Impact factor: 3.590

Review 9.  Prion diseases: what is the neurotoxic molecule?

Authors:  R Chiesa; D A Harris
Journal:  Neurobiol Dis       Date:  2001-10       Impact factor: 5.996

10.  Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration.

Authors:  G R Mallucci; S Ratté; E A Asante; J Linehan; I Gowland; J G R Jefferys; J Collinge
Journal:  EMBO J       Date:  2002-02-01       Impact factor: 11.598

View more
  31 in total

Review 1.  Allosteric function and dysfunction of the prion protein.

Authors:  Rafael Linden; Yraima Cordeiro; Luis Mauricio T R Lima
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

2.  PrP-grafted antibodies bind certain amyloid β-protein aggregates, but do not prevent toxicity.

Authors:  David Mengel; Wei Hong; Grant T Corbett; Wen Liu; Alexandra DeSousa; Laura Solforosi; Cheng Fang; Matthew P Frosch; John Collinge; David A Harris; Dominic M Walsh
Journal:  Brain Res       Date:  2018-12-26       Impact factor: 3.252

3.  Neurodegeneration induced by clustering of sialylated glycosylphosphatidylinositols of prion proteins.

Authors:  Clive Bate; Alun Williams
Journal:  J Biol Chem       Date:  2012-01-19       Impact factor: 5.157

Review 4.  Prions: Beyond a Single Protein.

Authors:  Alvin S Das; Wen-Quan Zou
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

5.  Sequence-dependent prion protein misfolding and neurotoxicity.

Authors:  Pedro Fernandez-Funez; Yan Zhang; Sergio Casas-Tinto; Xiangzhu Xiao; Wen-Quan Zou; Diego E Rincon-Limas
Journal:  J Biol Chem       Date:  2010-09-03       Impact factor: 5.157

6.  PrP Knockout Cells Expressing Transmembrane PrP Resist Prion Infection.

Authors:  Karen E Marshall; Andrew Hughson; Sarah Vascellari; Suzette A Priola; Akikazu Sakudo; Takashi Onodera; Gerald S Baron
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

7.  Context dependent neuroprotective properties of prion protein (PrP).

Authors:  Andrew D Steele; Zhipeng Zhou; Walker S Jackson; Chunni Zhu; Pavan Auluck; Michael A Moskowitz; Marie-Francoise Chesselet; Susan Lindquist
Journal:  Prion       Date:  2009-10-16       Impact factor: 3.931

8.  Signal sequence insufficiency contributes to neurodegeneration caused by transmembrane prion protein.

Authors:  Neena S Rane; Oishee Chakrabarti; Lionel Feigenbaum; Ramanujan S Hegde
Journal:  J Cell Biol       Date:  2010-02-15       Impact factor: 10.539

9.  In vivo generation of neurotoxic prion protein: role for hsp70 in accumulation of misfolded isoforms.

Authors:  Pedro Fernandez-Funez; Sergio Casas-Tinto; Yan Zhang; Melisa Gómez-Velazquez; Marco A Morales-Garza; Ana C Cepeda-Nieto; Joaquín Castilla; Claudio Soto; Diego E Rincon-Limas
Journal:  PLoS Genet       Date:  2009-06-05       Impact factor: 5.917

10.  Regulation of GABA(A) and glutamate receptor expression, synaptic facilitation and long-term potentiation in the hippocampus of prion mutant mice.

Authors:  Alejandra Rangel; Noelia Madroñal; Agnès Gruart; Agnès Gruart i Massó; Rosalina Gavín; Franc Llorens; Lauro Sumoy; Juan María Torres; José María Delgado-García; José Antonio Del Río
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.